The Portnoy Law Firm has announced a class action lawsuit on behalf of Erasca, Inc. investors who purchased securities between January 14, 2025 and April 26, 2026. The complaint alleges that Erasca and certain executives failed to disclose material information, including that preclinical data for its ERAS-0015 product was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections. Investors have until August 10, 2026 to file a lead plaintiff motion. The firm's founding partner has recovered over $5.5 billion for aggrieved investors.
Erasca IncClass action lawsuit alleges failure to disclose improper comparisons and patent/trade secret risks for ERAS-0015.
Revolution Medicines IncMentioned as the company whose data was improperly compared, but no direct impact on Revolution Medicines.